Ungerleider Jessica L, Christman Karen L
Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, California, USA.
Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, California, USA
Stem Cells Transl Med. 2014 Sep;3(9):1090-9. doi: 10.5966/sctm.2014-0049. Epub 2014 Jul 10.
Recently, injectable biomaterial-based therapies for cardiovascular disease have been gaining attention, because they have shown therapeutic potential in preclinical models for myocardial infarction (MI) and peripheral artery disease (PAD). Naturally derived (e.g., alginate, hyaluronic acid, collagen, or extracellular matrix-based) or synthetic (e.g., peptide or polymer-based) materials can enhance stem cell survival and retention in vivo, prolong growth factor release from bulk hydrogel or particle constructs, and even stimulate endogenous tissue regeneration as a standalone therapy. Although there are many promising preclinical examples, the therapeutic potential of biomaterial-based products for cardiovascular disease has yet to be proved on a clinical and commercial scale. This review aims to briefly summarize the latest preclinical and clinical studies on injectable biomaterial therapies for MI and PAD. Furthermore, our overall goal is to highlight the major challenges facing translation of these therapies to the clinic (e.g., regulatory, manufacturing, and delivery), with the purpose of increasing awareness of the barriers for translating novel biomaterial therapies for MI and PAD and facilitating more rapid translation of new biomaterial technologies.
近年来，基于可注射生物材料的心血管疾病治疗方法备受关注，因为它们在心肌梗死（MI）和外周动脉疾病（PAD）的临床前模型中显示出治疗潜力。天然来源的（如藻酸盐、透明质酸、胶原蛋白或基于细胞外基质的）或合成的（如基于肽或聚合物的）材料可以提高干细胞在体内的存活率和保留率，延长生长因子从块状水凝胶或颗粒构建体中的释放时间，甚至作为单一疗法刺激内源性组织再生。尽管有许多有前景的临床前实例，但基于生物材料的产品对心血管疾病的治疗潜力尚未在临床和商业规模上得到证实。本综述旨在简要总结关于MI和PAD的可注射生物材料疗法的最新临床前和临床研究。此外，我们的总体目标是突出这些疗法转化到临床所面临的主要挑战（如监管、制造和递送），以提高对MI和PAD新型生物材料疗法转化障碍的认识，并促进新生物材料技术更快地转化。
